Roche Says Sales Growth Will Slow This Year

The transcript discusses Roche's expectations for sales growth, focusing on new drugs to offset losses in oncology. It highlights Hemlibra's potential in hemophilia treatment and the impact of new entrants like Amazon in the healthcare industry. The CEO addresses drug pricing differences between the US and Europe, emphasizing FDA's role in accelerating approvals. Roche's M&A strategy, including the acquisition of Ignita, is also covered.

How does Roche plan to compensate for the entry of biosimilars?

What does Roche's CEO believe about the impact of FDA approval timelines on drug prices?

What is Roche's strategy regarding mergers and acquisitions?